Analysis of Post-operative Adjuvant Chemotherapy Versus Adjuvant Chemoradiation Therapy Outcomes in Non-metastatic Cholangiocarcinoma: an NCDB Review.
Adjuvant treatment
Chemotherapy
Cholangiocarcinoma
Radiation therapy
Journal
Journal of gastrointestinal cancer
ISSN: 1941-6636
Titre abrégé: J Gastrointest Cancer
Pays: United States
ID NLM: 101479627
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
accepted:
19
08
2021
pubmed:
7
9
2021
medline:
8
9
2022
entrez:
6
9
2021
Statut:
ppublish
Résumé
Each year, approximately 8000 cases of cholangiocarcinoma are recorded in the USA. Surgical resection is considered to be the only curative option. Despite surgery as a curative approach, many patients will require adjuvant therapies in the form of chemotherapy (ChT) or chemoradiotherapy (CRT). As such, we sought to analyze outcomes in patients with non-metastatic cholangiocarcinoma receiving adjuvant ChT or CRT following surgical resection. We queried the National Cancer Database (NCDB) for patients with a diagnosis of non-metastatic cholangiocarcinoma between the years 2010 and 2015 who underwent adjuvant ChT or CRT following surgery. Overall survival (OS) was calculated using Kaplan Meier method. Cox proportional hazard ratios were used to identify predictors of overall survival, and logistic regression was used to identify predictors of receiving each treatment. A total of 875 patients were identified who met the above eligibility criteria. Of these patients, 818 received adjuvant chemotherapy alone with 57 patients receiving adjuvant chemoradiation therapy. The median OS in patients receiving CRT was 19.8 months versus 11.9 months for ChT (p value < 0.0238). The 1- and 5-year survival rates between ChT and CRT were 50% vs 61% and 6% vs 13%, respectively (hazard ratio 0.7005; 95% CI 0.51-0.97; p value < 0.0294). The results of this study suggest a potential benefit of chemoradiation therapy in the adjuvant setting, although the trends appear to show rare utilization. Given the limitations of our study, prospective corroboration is warranted.
Sections du résumé
BACKGROUND
BACKGROUND
Each year, approximately 8000 cases of cholangiocarcinoma are recorded in the USA. Surgical resection is considered to be the only curative option. Despite surgery as a curative approach, many patients will require adjuvant therapies in the form of chemotherapy (ChT) or chemoradiotherapy (CRT). As such, we sought to analyze outcomes in patients with non-metastatic cholangiocarcinoma receiving adjuvant ChT or CRT following surgical resection.
METHODS
METHODS
We queried the National Cancer Database (NCDB) for patients with a diagnosis of non-metastatic cholangiocarcinoma between the years 2010 and 2015 who underwent adjuvant ChT or CRT following surgery. Overall survival (OS) was calculated using Kaplan Meier method. Cox proportional hazard ratios were used to identify predictors of overall survival, and logistic regression was used to identify predictors of receiving each treatment.
RESULTS
RESULTS
A total of 875 patients were identified who met the above eligibility criteria. Of these patients, 818 received adjuvant chemotherapy alone with 57 patients receiving adjuvant chemoradiation therapy. The median OS in patients receiving CRT was 19.8 months versus 11.9 months for ChT (p value < 0.0238). The 1- and 5-year survival rates between ChT and CRT were 50% vs 61% and 6% vs 13%, respectively (hazard ratio 0.7005; 95% CI 0.51-0.97; p value < 0.0294).
CONCLUSION
CONCLUSIONS
The results of this study suggest a potential benefit of chemoradiation therapy in the adjuvant setting, although the trends appear to show rare utilization. Given the limitations of our study, prospective corroboration is warranted.
Identifiants
pubmed: 34486086
doi: 10.1007/s12029-021-00696-w
pii: 10.1007/s12029-021-00696-w
pmc: PMC9436866
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
700-708Informations de copyright
© 2021. The Author(s).
Références
Cancer Manag Res. 2019 Dec 30;11:10871-10882
pubmed: 31920396
Lung Cancer. 2019 Feb;128:127-133
pubmed: 30642444
BMC Cancer. 2019 Feb 28;19(1):185
pubmed: 30819129
Liver Int. 2019 May;39 Suppl 1:143-155
pubmed: 30843343
Lancet Oncol. 2019 May;20(5):663-673
pubmed: 30922733
Nat Rev Clin Oncol. 2018 Feb;15(2):95-111
pubmed: 28994423
Thorac Cancer. 2020 Feb;11(2):305-310
pubmed: 31860940
Ann Surg Oncol. 2019 Aug;26(8):2549-2557
pubmed: 31020501
Ann Surg Oncol. 2015 Dec;22 Suppl 3:S1133-9
pubmed: 25976862
Radiother Oncol. 2018 Sep;128(3):575-583
pubmed: 29801723
JAMA. 2012 Jul 11;308(2):147-56
pubmed: 22782416
Cancer. 2002 Oct 15;95(8):1685-95
pubmed: 12365016
Ann Surg Oncol. 2015 Jul;22(7):2209-17
pubmed: 25476031
Ann Surg Oncol. 2008 Nov;15(11):3147-56
pubmed: 18754070
Ann Surg Oncol. 2017 Dec;24(13):3926-3933
pubmed: 28952140
Asian Pac J Cancer Prev. ;17(10):4735-4739
pubmed: 27893205
Ann Surg. 1996 Nov;224(5):628-38
pubmed: 8916878
Ann Surg. 1999 Dec;230(6):776-82; discussion 782-4
pubmed: 10615932
Ann Surg. 1996 Apr;223(4):384-94
pubmed: 8633917
N Engl J Med. 2010 Apr 8;362(14):1273-81
pubmed: 20375404